Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >


biginvest
Posted on: Oct 8 2019, 05:02 PM


Group: Member
Posts: 45

Does the trading halt only affect the ASX ?
  Forum: By Share Code

biginvest
Posted on: Jun 20 2019, 07:38 AM


Group: Member
Posts: 45

What about Astaxanthin ? It should protect the skin from sunlight.

( and in the 80 s they sold Canthaxanthin for tanning )
  Forum: By Share Code

biginvest
Posted on: Apr 12 2017, 02:31 PM


Group: Member
Posts: 45

https://www.youtube.com/watch?v=liOVwlnz6mg


Florian Homm about Clinuvel
  Forum: By Share Code

biginvest
Posted on: Oct 16 2016, 08:41 PM


Group: Member
Posts: 45

http://www.wallstreet-online.de/nachricht/...ag-florian-homm
  Forum: By Share Code

biginvest
Posted on: Oct 11 2016, 10:28 PM


Group: Member
Posts: 45

$14,20
  Forum: By Share Code

biginvest
Posted on: May 18 2016, 01:49 AM


Group: Member
Posts: 45

https://www.g-ba.de/downloads/92-975-1359/2...famelanotid.pdf

22000€ per implant confirmed for germany
3-4 implants per year for adults suggested
450-900 patients in germany
  Forum: By Share Code

biginvest
Posted on: May 8 2016, 03:43 AM


Group: Member
Posts: 45

I dont know if this is common knowledge but for me this was new when i read today that in Switzerland the reimbursemnet for Scenesse is stopped because of the price change which made it more expensive. On the german EPP site i found an online petition from the patients who try get Scenesse again after they had accesss to it since 2012.
  Forum: By Share Code

biginvest
Posted on: May 7 2016, 10:27 PM


Group: Member
Posts: 45

The BfarM is the german federal institute to ensure the safety of medication and the article i posted is the official confirmation from BfarM that all hurdles for Scenesse are out of the way and the application of Scenesse in Germany can start.
  Forum: By Share Code

biginvest
Posted on: May 7 2016, 07:57 PM


Group: Member
Posts: 45

http://www.epp-deutschland.de/mediapool/21...reibenBfArM.pdf
  Forum: By Share Code

biginvest
Posted on: Mar 24 2016, 06:37 PM


Group: Member
Posts: 45

That was before the 10:1 reverse split so the sp was about 70 cent,
  Forum: By Share Code

biginvest
Posted on: Mar 24 2016, 06:06 PM


Group: Member
Posts: 45

Attached Image





We were at an equivalent share price of 7€ in 2007 maybe some of you remember? At that time without approval, maybe with some manipulation by ACM ( Mr Homm) :-)
By the way Mr Homm published a new book recently and i read it. Its called ENDGAME and describes the crash of the financial markets in near future that he expects.
So better spent the paper money in something with substance like Clinuvel.
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

biginvest
Posted on: Dec 24 2015, 08:24 AM


Group: Member
Posts: 45

Usually the stock goes up in January

2016 i think the stock will raise in January because the chance / risk ratio is amazing and personally i bet we will see a rocket rise because we will see big revenues in 2016
  Forum: By Share Code

biginvest
Posted on: Sep 23 2015, 03:55 AM


Group: Member
Posts: 45

http://uk.businessinsider.com/martin-shkre...&IR=T"]http://uk.businessinsider.com/martin-shkreli-of-turing-twitter-2015-9?r=US&IR=T[/url]
  Forum: By Share Code

biginvest
Posted on: Sep 8 2015, 04:00 AM


Group: Member
Posts: 45

http://www.bild.de/ratgeber/gesundheit/sel...95230.bild.html


Article on a famous newspaper in Germany yesterday
  Forum: By Share Code

biginvest
Posted on: Aug 1 2015, 02:41 PM


Group: Member
Posts: 45


This was Retrophins agenda regarding Clinuvel:
(Form 10-Q on 11-May-2015)



On July 17, 2014, we made a proposal to the board of directors of Clinuvel Pharmaceuticals Limited ("Clinuvel") to acquire all of the outstanding shares of Clinuvel for either 0.175 shares of common stock of the Company or $2.03 in cash per share for an aggregate purchase price of approximately $89 million. The Company has since abandoned this strategy and plans to liquidate its positions in Clinuvel over time. As of March 31, 2015, we had remaining approximately $6.2 million of the outstanding shares of Clinuvel. Our goal is ultimately to dispose of our equity interest in Clinuvel and use the cash generated from stock sales for working capital purposes. However, these shares may not appreciate in value and, in fact, may decline value. Accordingly, we may not be able to realize gains from our interest in Clinuvel, and any gains that we do realize on the disposition of any of these shares may not be sufficient to offset any other losses we experience.


So i think we all can be glad they are off our back now.
  Forum: By Share Code

biginvest
Posted on: Jul 29 2015, 02:41 PM


Group: Member
Posts: 45

I think we have seen the bottom now of the shareprice. It is very good news that the sell pressure from Retrophin is over now.
With the next news which i expect beeing good we will see much higher shareprice soon :-)
  Forum: By Share Code

biginvest
Posted on: Jul 20 2015, 12:56 PM


Group: Member
Posts: 45

Some month ago on another Clinuvel board i read a comment of an investor saying why are you investing in Clinuvel when there are so many better chances, he would invest in Hanergy now and the shareprice is going through the roof now.
That was in May if i remember correctly. Some days later that stock crashed and is now discontinued for trading since then because of manipulation of the shareprice.

What i wanna express her is, i prefer this stock which seems to be a lame duck but behind the scenes it is building up intrinsic value and sooner or later the shareprice will move to this direction.
I
  Forum: By Share Code

biginvest
Posted on: Jul 10 2015, 03:00 AM


Group: Member
Posts: 45

Afamelanotid verbessert Sonnentoleranz bei erythropoetischer Protoporphyrie
Freitag, 3. Juli 2015

New York – Subkutane Implantate, die das synthetische „Bräunungshormon“ Afamelanotid freisetzen, haben in zwei Phase 3-Studien im New England Journal of Medicine (2015; 373: 48-59) Patienten mit einer erythropoetischen Protoporphyrie einen längeren Aufenthalt im Freien ermöglicht und dadurch die Lebensqualität verbessert.

Die erythropoetische Protoporphyrie ist eine seltene Erbkrankheit, die durch eine verminderte Aktivität des Enzyms Ferrochelatase verursacht wird. Ferrochelatase ist im letzten Schritt der Häm-Synthese für den Einbau des Eisen-Ions in den Protopor­phyrin-Ring zuständig. Der Gendefekt führt zu einer erhöhten Konzentration von Protoporphyrin in den Erythrozyten und den Blutgefäßen.

In der Haut kommt es nach Absorption von Lichtwellen zur Bildung von Sauerstoff­radikalen, was eine schmerzhafte „Lichtallergie“ auslöst. Schon nach wenigen Minuten unter der Sonne kommt es zu einem brennenden Schmerz an Händen und im Gesicht, anschließend zu einer Schwellung und Rötung. Da es keine kausale Therapie der Erkrankung gibt, sind die Patienten auf einen Lichtschutz angewiesen. Da dieser nicht an allen Stellen durch Kleidung möglich ist, ziehen sich viele Patienten aus dem öffentlichen Leben zurück.

Eine Alternative besteht in einer Bräunung der Haut. Sie kann durch eine synthetische Variante des Melanozyten-stimulierenden Hormons erreicht werden. Forscher der Universität von Arizona hatten Afamelanotid, das deutlich stärker als sein natürliches Pendant wirkt, ursprünglich als Mittel zur Hautkrebsprophylaxe entwickelt. Es wurde in dieser Indikation jedoch niemals zugelassen.

Seit einiger Zeit wird Afamelanotid in der Schweiz und in Italien von Patienten mit erythro­poetischer Protoporphyrie eingesetzt. In Italien ist es seit 2010 offiziell zugelassen. Der australische Hersteller Clinuvel Pharmaceuticals, Melbourne, entschloss sich aufgrund der guten Erfolge zur Durchführung von zwei klinischen Studien. In Europa konnten 74 Patienten und in den USA 94 Betroffene der seltenen Erkrankung (die Prävalenz wird auf 1 zu 100.000 geschätzt) für die Studie gewonnen werden.

zum Thema
Abstract der Studie im NEJM
Pressemitteilung der Icahn School of Medicine'
Pressemitteilung des Herstellers
European Porphyria Initiative
Pressemitteilung der EMA vom Oktober 2014
Alle erhielten ein subkutanes Implantat, das über 60 Tage Afamelanotid oder Placebo an den Körper freisetzt und dann ausgetauscht werden muss. Nach sechs Monaten (USA) oder neun Monaten (Europa) bestimmten die Teilnehmer, wie lange sie sich in der Sonne aufhalten konnten, bevor der Schmerz einsetzte. Wie ein Team um Robert Desnick von der Icahn School of Medicine in New York berichten, verlängerte sich die Toleranzzeit in USA von 40,8 auf 69,4 Stunden. In Europa stieg sie von 0,8 auf 6,0 Stunden an. Die Zahl von phototoxischen Reaktionen wurde hier von 146 auf 77 gesenkt. In den USA wurden die Ergebnisse durch eine direkte Photoprovokation bei 21 Patienten bestätigt.

Die Unterschiede zwischen der US-amerikanischen und der europäischen Studie erklären sich aus der unterschiedlichen Dauer der Anwendung und der geographischen Breite. Nach den von Desnick vorgestellten Ergebnissen ist die Therapie sicher. Bedenken, dass die Therapie langfristig zu einem Anstieg der Melanomrate führt, haben die Autoren nicht. Sie hoffen im Gegenteil darauf, dass die stärkere Bräunung die Patienten im Nebeneffekt vor dem Hautkrebs schützen könnte.

Die europäische Arzneimittel-Agentur hat sich bereits von den Ergebnissen überzeugen lassen. Das Mittel wurde kürzlich zugelassen. Der Hersteller möchte es als Scenesse vermarkten. In den USA ist das Mittel noch nicht zugelassen.

© rme/aerzteblatt.de
  Forum: By Share Code

biginvest
Posted on: Jun 27 2015, 04:11 AM


Group: Member
Posts: 45

It is so frustrating...after more than 10 years in Epitan / Clinuvel first time i was in the green after approval.
Everyone told then it will never go lower than 5 $ again and i bought in again.
Now i am so deep in the red again i never believed.
I thought after approval we gained some substancial.
Before it was only speculating but now we have a product.
But the sp falls and falls and now we stand like years before when we had nothing.
I think i must be a masochist having this stock.
  Forum: By Share Code

biginvest
Posted on: Jun 21 2015, 07:27 PM


Group: Member
Posts: 45

I just read an article about albinism in Africa .1:10000 are affected by this in Africa, worldwide 1:20000.
Especially in Africa they are threatened by the sun which can cause severe eye and skin damage.
Does anybody know if Scenesse can help people which are affected by albinism?
  Forum: By Share Code

biginvest
Posted on: Jun 20 2015, 03:42 PM


Group: Member
Posts: 45

Yesterday i got a letter from my broker that Clinuvel via NASDAQ OMX has requested the name of adress from me and my volume of Clinuvel shares..
It s a legal act after Subsection 672A and 672B of the corporations act of disclosure.

I have no idea what this is about. Anyone of you?
  Forum: By Share Code

biginvest
Posted on: Jun 7 2015, 06:00 AM


Group: Member
Posts: 45

I think there will be a demand of Scenesse by Fitzpatrick 1 and 2 too once its available for EPP sufferers.Dont u think?
  Forum: By Share Code

biginvest
Posted on: May 19 2015, 04:17 AM


Group: Member
Posts: 45

http://www.ema.europa.eu/docs/en_GB/docume...WC500182309.pdf



http://www.ema.europa.eu/ema/index.jsp?cur...b01ac058001d124




i am not sure if this was posted already, i just found that today.
  Forum: By Share Code

biginvest
Posted on: May 13 2015, 04:14 AM


Group: Member
Posts: 45

Volume today in Germany unusual good with 7225 and an increase in Sp of 1,5%
  Forum: By Share Code

biginvest
Posted on: May 12 2015, 06:26 AM


Group: Member
Posts: 45

Dont make ur judgement about PW only about the SP.
He managed to take our product over the hurdles of EMA approval .

We have a good product now and the future looks bright ahead why weep all the time ?
I am sure when the SP recovers all sing hymns about PW again..but deal with bad times too and dont loose hope.
  Forum: By Share Code

biginvest
Posted on: May 9 2015, 02:50 PM


Group: Member
Posts: 45

asx
  Forum: By Share Code

biginvest
Posted on: Apr 18 2015, 08:14 PM


Group: Member
Posts: 45

Last year in July Retrophin made the takeover proposal for $2,17 per share.
Clinuval declined it because this bid materially undervalues Clinuvel .
That was prior to the approval by the EMA.
Now we have approval and the company is negotiating the prices with the EU countries and is about to start distributing the Scenesse implants and starts earning good money.
And at this moment the sp falls back to 2,76$ ?
The market is led by emotions very much but when i look at the facts i am sure
this price is a joke and undervalues the company dramatically.
I am sure after we are hearing good news the sp will rise again but when we are at 2,76$ and move
up 50% we still are only at 4$ where we were month ago.I have been in this stock since Epitan times more than 10 years but the last month were little frustrating.
Waiting for good news soon.
  Forum: By Share Code

biginvest
Posted on: Mar 7 2015, 06:00 PM


Group: Member
Posts: 45

maybe you mean this ?
Attached File(s)
Attached File  42v930mbmnkspz.pdf ( 278.95K ) Number of downloads: 122

 
  Forum: By Share Code

biginvest
Posted on: Mar 4 2015, 06:11 AM


Group: Member
Posts: 45

On a day like this where our baby is down 9% without any bad news let us dream a little.
Look at this beautiful chart. Its from a biotech company who developped an implant too that dissolves in the body.
Instead of implantation in the skin is an implant directly into the eye to treat makula problems.
But i still dream that Clinuvels chart will look as bright as this chart too in future.
Attached Image

  Forum: By Share Code

biginvest
Posted on: Feb 8 2015, 02:13 AM


Group: Member
Posts: 45

This is a talk of Florian Homm who supported Clinuvel some years ago as manager of ACM.

He is talking about Clinuvel starting min 36:00

It is in german, but the main message is that this is a company with tremendous future and he predicts the shareprice to go much higher.


https://www.youtube.com/watch?v=f8cA-OXU0xg



I aprreciate your positiveness "near future" that is what the board needed.
I remember the euphoria after approval followed by a depression without real reason.
Yes the sp sucks, maybe Retrophin dumps shares to try a new takeover offer when the sp is low enough? Who knows.
But what i am sure of in agreement with Philipp Wollgen this will pay out in the end .
  Forum: By Share Code

biginvest
Posted on: Jan 3 2015, 08:06 PM


Group: Member
Posts: 45

Over the last years we allways saw a recurring pattern regarding the shareprice of cuv.
In January a run up followed by a decline over the rest of the year and the december
was allways a very bad month for the sp.
When i asked for the possible reason on this board some time ago i got an
explanation like many would sell before the end of the year because of tax reasons
and in January at the beginning of a new fiscal year many would return.
I don´t know if that is really the reason.
What do you expect this year. Did the approval change this pattern or do some of you expect
this year to be the same and we will see a run up again now in January?

  Forum: By Share Code

biginvest
Posted on: Dec 21 2014, 09:56 PM


Group: Member
Posts: 45

Hallo,

this is a post i found ,made by Mr Forian Homm addressing Uhonic, which most of us know i think.
The reading of this letter for me was very interesting because Mr Homm has a long history with clinuvel and
tells of some insights and gives his evaluation of the future course of clinuvel.
It also changed my mind regarding Mr Homm who seems to have changed totally and made a metamorphorsis from his time as a financial tycoon to now.
Maybe the desease he suffers from ( MS) changed him that way and it seems he became a religious man.
But talking of clinuvel he strengthened my believe that from an investors pov all the suffering in the past was worth it and now the future looks brighter than ever.

I wish all of you a merry XMas

Greetings from Germany




Dear Uhohinc,

your research is amazingly in depth. You even quoted my book, Rogue Financier. That is thorough stuff.. I am leaving this little post with you. On November 5th I will hold a speech at a University in Erding, Bavaria, north of Munich before a few hundred students and about a dozen people from the media. Clinuvel will feature quite prominently in this speech as the investment, providing me with great emotional gratification especially after the EMA approval. I was fortunate to finance this company. Quite frankly, our funding prevented this jewel from going bust and we actively searched the market for credible, science oriented management. I leave this little commentary with you to make available to others on share scene and other boards. I have followed Clinuvel very closely for years even during my 15 months in prison fighting extradition to America. I will touch on a few issues (not just these very narrow financial concerns) that may be of interest to you and others:

Valuation:
In the absence of serious research the shares are absurdly misplaced. During my illustrious career I received numerous investment awards (european hedge fund manager of the year, top us specialty fund manager, number one germany fund, European pension fund, blah blah blah). I have written over 500 research reports for the likes of Fidelity, Merrill Lynch, tweedy Browne, VMR AG, ACMH Group etc etc... I have a reasonable idea of this business. Here we go:
Revenues of USD 40 to 70 Million for EPP is realistic. But get to the pretax or net profit figures! On EPP alone, Clinuvel may trade at only 5 times 2016 or 2017 earnings. I have not the slightest doubt that EPP alone is worth AUD 5-7 per share right now. You have to look at Vitiligo separately! This a sum of the parts evaluation. I was the original proponent to encourage CUV to consider Vitiligo, but Dr. Wolgen took it the critical step further: not as a stand-alone treatment but as a combination therapy. Here are some facts which will blow your mind: there are no less than 1.2 million vitiligo treatments per year. Some world class sources say the number may be between 1.5 and 1.8 Million. I love using lowish numbers in my models. If the low balling works and I do not have to twist the math - so much the better. It is utterly realistic that CUV may get USD 5K to 7K per vitiligo treatment. It is increasingly evident, that the combination therapy is so much more effective it will over a few years largely wipe out the traditional treatments. I would be very surprised if CUV does not reach abut half of the market in annual vitiligo treatments, certainly no less than 500,000 treatments a year as the market will quickly learn about CUV's vastly superior product. USD 3.5 Billion in sales. What do you thing the bit margins are on this product? It is not unrealistic that CUV generates USD 1 Billion or more in net profit by 2018/2019. Some of the things you say make serious sense as well. How about off-label use for extreme vitiligo cases? Or how about the hundreds of thousands who get skin cancer after organ transplants. Would CUV work there. Worth a try certainly. Always better than the risk of malignant, at times deadly skin cancer. Or how about those extreme Fitzgerald 1 types ultra prone to get skin cancer even with only modest sun exposure. What is beautiful about the modeling now is that with EMA approval and 95 percent likelihood of FDA approval the shares have basically done nothing. There is not a single first rate research report on CUV! That is incredible and difficult to fathom. It is also a once in a lifetime investment opportunity. Do not get lost in all the blah-bla micro details in these posts. Buy, put away and then cash out of your ten, twenty, thirty or forty bagger. Yes, that is possible and probable. There is no chance this undervaluation persists for more than 6 to 12 months. None. Vitiligo is progressing quite quickly, quarterly EPP profit figures will show exponential growth and patient numbers in the US and Europe may even surprise on the upside. For a proper valuation you need to strip out all R&D, OH and simply take COGS and Marketing/Sales. Vitiligo, the same but get ready for USD 50 Million to get to full FDA approval. If I use 50 million shares outstanding (conservative) CUV is worth 12 to 15 AUD per share at this very moment. 300 for EPP and 450 for Vitiligo. In an organized auction process, CUV would easily get USD 10 per share. Cash!

Threats:
There are three: A takeover. CUV, at this price is a sitting duck. It needs to be on NASDAQ asap. Top senior management (mostly Dr. Wolgen) needs to stay for at least the next 5 years and he needs to upgrade his team for a rather demanding Vitiligo approval process. Unless you have been in this space for a few decades (I have) you do not appreciate obtaining regulatory approval for a treatment which simply does not fit into the classical approval methodology (placebo or double blind design was absolutely not possible). The Scenesse approval by the EMA was the first ever, which integrated patient/doctor groups in the decision making process. That is a monumental achievement. The product pricing is amazingly good and much better than I ever imagined when I got involved about a decade ago. I see shareholders moaning about compensation levels. That is beyond absurd. This company is already global, operating in Europe, Australia, Singapore and the US. Compared to those companies compensation levels are well below average and what I view as a serious risk - management only has a tiny stake in this company. Their interest are not properly aligned with shareholders. It is always the same risk. A well payed manager may sell out a company well below price if his personal stake is small. He may opt for a fat golden parachute instead. CUV top management owns about 4 percent of the company. Get real. 10 percent, some for EPP and milestones like NASDAQ and the mother of all approvals vitiligo. This is a serious risk. Of course an opportunistic takeover at AUD 7, 10, 20 or even 30 is another heavy risk. You are sitting on a potentially huge gold mine and someone literally steals it from under you. The third serious risk is execution. Dr. Wolgen is key and few very focused members of senior management. Retain, retain, retain and motivate. So simple. Upgrade that board and senior management for NSDAQ because this is no longer the Queensland Cup. There are so many clowns running around (an Australian dentist (madman on share scene), Retrophin under Shkreli, some suspect, "concert party" hedge funds) who have no idea what has been achieved and what remains to be done. This stuff is micro-management, persistence requiring the highest possible degree of credibility and operational focus. Regulators hate disruptions. Management disruptions, and all too frequent board shuffles are toxic and at best delay regulatory procedures. At worst they can derail them entirely. I have hired and fired hundreds of senior executives. Those wannabe entrepreneurs offer nothing but populistic generic hogwash. Madman has a sharp mind, but stick to the research Mr. Jones. I like what I read from you and Poontz as well, but get the big picture....grasp the complexity.

The Human Dimension:
I do not own a single share. I will not own a single share. I used to serve Mammon. I have zero motivation to pump CUV. I want millions to be treated and cured. I want people to be hopeful. My masters are God, Jesus and Mary. I am so grateful Scenesse was approved. I wish all of you great fortunes with CUV, but give some back to great causes when you cash in that CUV check. On a fifteen year viewpoint, Scenesse may even succeed to help those most likely to contract skin cancer. Vitiligo is very damaging emotionally. EPP suicide rates are very, very high. At least half of those obtaining organ transplants get skin cancer. Hundreds of thousands of lives may be saved, millions will improve. Many of these folks have been without hope. That is what pleases me most. CUV gives hope, not just superior investment returns. It gives me a kick, that between all the raids, dozens of IPOs, short sales, VC deals and so forth there is this one company which makes me happy to bee associated with: Clinuvel. How often in life can you invest and reap a serious fortune and do something really good at the same time? Well? I have done hundreds of deals in a thirty year career. Such a benign and virtuous mix is incredibly rare: once in a lifetime for me. So you intense investors.....do not forget the human dimension and consider if CUV becomes this multi-bagger as I am predicting (anybody who had bought Rogue Financier and bought CUV shares would have made more than 300 percent), give to those in need and those who are less fortunate than you.

Viel Glück

Florian
  Forum: By Share Code

biginvest
Posted on: Dec 8 2014, 07:19 AM


Group: Member
Posts: 45

I attached the Notice of change of interests of substantial holder :

Attached File  42v930mbmnkspz.pdf ( 278.95K ) Number of downloads: 157
  Forum: By Share Code

biginvest
Posted on: Nov 19 2014, 09:52 AM


Group: Member
Posts: 45

Attached Image

I think that could be right.In February 2007 the sp was above 70 cent.I attached the longtime chart(Euro), i hope that works.
That was 7 years pre 1.st approval but that was the time when Florian Homm at AGM played with this stock i guess.
  Forum: By Share Code

biginvest
Posted on: Sep 6 2014, 09:47 AM


Group: Member
Posts: 45

I remember 8 years ago the sp in germany was 70 ct what equals 7€ after the reverse split and now we are at 21 ct talking in pre reverse split so i am not getting excited by now :-).
But obviously the sp will go heading north till EMA decision so i am sure 3 weeks from now we ll see maybe 4-5€ in Germany and then depending on the outcome maybe it doubles or triples or
we are busted. But exciting times after almost 10 years in this stock finally the endgame begins.
  Forum: By Share Code

biginvest
Posted on: Jul 19 2014, 11:55 AM


Group: Member
Posts: 45

Yesterday on german stock market unusual high volumes traded >55000 with a sp recovery of 8,5%.
EMA delay sucks, i hope we will finally see a decision this year.
  Forum: By Share Code

biginvest
Posted on: Jan 4 2014, 09:34 PM


Group: Member
Posts: 45

Attached Image



I am wondering why the Clinuvel shareprice seems to follow a regulary pattern as in the last 2 years there allways was
a substantial increase in shareprice in January followed by a decline at the end of each year.

Sure i am happy our baby is still breathing and this time i hope it will grow and become stronger every day :-)
  Forum: By Share Code

biginvest
Posted on: Dec 26 2013, 03:59 PM


Group: Member
Posts: 45

Merry Xmas to all loyal Clinuvel Shareholders.
This year was a real rollercoaster ride. In March the Shareprice boosted like a rocket due to expected EMA approval.
The bigger was the disappointment when there was a further delay.
Now the shareprices crawls at all time lows even the chances of approval are still good but the trust in this stock seems to have gone.
As for me i still hope and believe that next year will be THE year for us either that way or the other.
So fasten your seat belts for a bumby ride as the journey approaches the finish line.
  Forum: By Share Code

biginvest
Posted on: Nov 5 2013, 08:45 PM


Group: Member
Posts: 45

In Germany Clinuvel is a pennystock again with 99,7 ct. down 5% today.

The decrease of shareprice this year is very disapponting especially when you see the raise of the stock market in general.

I didnt lost hope though in this company and hope next year we will have approval of EMA but this year the shareprice is a disaster :-(
  Forum: By Share Code

biginvest
Posted on: Mar 3 2013, 10:57 PM


Group: Member
Posts: 45

Maybe some of you remember Florian Homm,former manager of ACM (Absolute Capital Management).

He just was on german Television on ZDF in a Talkshow called "Peter Hahne "

They invited him as a representative of capitalism and he was in discussion with Sarah Wagenknecht representative of german party "Die LInke "
a neo communism party.

What may be interesting is that he mentioned Clinuvel in this discussion ,he said this:

He told he rescued Clinuvel with investing 80 Mio $ when the company was facing banruptcy (must be 2006 or 2007)
He told the company now can help 20000 EPP patients and in near future 50 Mio who suffer from VItiligo.

He mentioned Clinuvel by name.

At the end of the show the representer asked him how he would invest 10000€ and he told he would invest in the company he mentioned in his book which is in fact Clinuvel.


Just some little info to break the silence while we all hope EMA approval is at the door and we hear the knocking.

Good luck to all long time investors like me :-)
  Forum: By Share Code

biginvest
Posted on: Sep 5 2012, 03:42 AM


Group: Member
Posts: 45

Todays news coverage in a very popular german newspaper called BILD Zeitung.


Mikro-Implantat macht ohne Sonne braun

Braunwerden ohne Sonne und ohne UV-Schäden – was sich anhört wie ein wilder Sonnen-Traum, könnte schon bald Realität werden. Australische Forscher haben ein Mini-Implantat erfunden, das die Haut vor der Sonne schützt. Es steht kurz vor der Marktzulassung.
Scenesse heißt das Wundermittel, das über der Hüfte unter die Haut injiziert wird. Es ist nur so groß wie ein Reiskorn! Wenige Tage nach dem Einsetzen bräunt sich die Haut und bleibt dann bis zu 60 Tage so. Das Implantat zersetzt sich von selbst.
Entwickelt wurde Scenesse von der australischen Pharmafirma Clinuvel, die sich auf innovative Lichtschutzprodukte spezialisiert hat.
Das Mini-Implantat enthält das Hormon Melanotan, das den Körper zur Bildung von Melanin anregt. Melanin ist der braune Hautfarbstoff, den die Haut auch bei Sonnenbestrahlung ausschüttet und der dann vor den UV-Strahlen schützt. Die Bräunung der Haut ist die Immunantwort auf UV-Strahlen.

Wird die Ausschüttung von Melanin nun durch Scenesse angeregt und nicht durch UV-Strahlen, fällt die zellschädigende Wirkung des Sonnenlichts weg. Zudem schützt das Melanin die Haut vor UV-Schäden, wie Hautalterung und Krebs.
Der Wermutstropfen: Scenesse ist nur für den Einsatz bei bestimmten Krankheiten vorgesehen.
„Scenesse wurde als Medikament für schwere Hautkrankheiten entwickelt. Keine Gesundheitsbehörde der Welt kann ein künstliches Hormon wie Melanotan zum kosmetischen Einsatz zulassen,“ sagt Clinuvel-Sprecher Lachlan Hay.
Bedeutet: Scenesse muss immer von einem Arzt verschrieben werden. Für Menschen mit Lichtkrankheiten könnte Scenesse aber der absolute Hoffnungsträger sein, Tests mit über 600 Teilnehmern waren erfolgreich, Nebenwirkungen gab es kaum
Schon nächstes Jahr könnte das Medikament laut Hay in Deutschland gegen die seltene Hautkrankheit Erythropoetische Protoporphyrie (EEP) eingesetzt werden. Bei der Stoffwechselstörung EEP reagieren die Erkrankten extrem empfindlich auf UV-Licht, empfinden Schmerzen bei Sonnenschein.
Scenesse kann außerdem bei Lichturtikaria, polymorpher Lichteruption oder UV-Empfindlichkeit nach Organtransplantationen eingesetzt werden.
Auf jeden Fall wird die Sonne für viele bald weniger Bedrohung, sondern mehr Freude sein...
  Forum: By Share Code

biginvest
Posted on: Aug 9 2011, 04:34 AM


Group: Member
Posts: 45

Hi guys..anyone has idea what is this?

CLINUVEL PHARMACEUTICALS LTD
Aktie Nasdaq 08.08.11
20:00 160,00
USD 158,31
9367,46% 10.014
  Forum: By Share Code

biginvest
Posted on: May 28 2011, 03:52 AM


Group: Member
Posts: 45

High Volume today in germany.

Stuttgart 17712 +11,8%

Frankfurt 28049 +8%

Maybe some good news ahead?
  Forum: By Share Code

biginvest
Posted on: Jul 7 2008, 02:35 PM


Group: Member
Posts: 45

In reply to: Rosewood on Monday 07/07/08 08:32am

While they are outlining its potential for cosmetic industry u can see this meditan website for
some seconds.
They only say that on some webpages they already offer this stuff for cosmetic purposes.
But they are warning that its unsafe and not authorized.
I took a look at it myself and this meditan seems to be a dermatologist in munich,offering
it for cosmetic use.
I think she orders it from China to offer her patients this kind of teatment.
In my eyes its nothing we have to worry about.

But i wanna add something to the Zuerich trials.
Patients and doctors were absolutely positive about CUV 1647.
It works.

Thx for reading my post

Greetings from Germany
  Forum: By Share Code

biginvest
Posted on: Jul 7 2008, 02:56 AM


Group: Member
Posts: 45

Hallo !
I m from Germany and i watched this video twice.

ITS DEFINITELY ABOUT CUV1647 by CLINUVEL !!
(they say its from australian company and during video u can see an envelope,the implant
was transportet in.
On envelope you can see CUV 1647 and the name and adress of Clinuvel)



They make two examples about 2 indications.

1. Sunintolerance

2.Skincancer

They definitely are talking about ongoing PH 3 testings at a Zuerich hospital
(for sunintolerance)

They mention that this drug will be available 2009.


The 2nd part of the video is about notauthorized melanotan which u can order mostly in
China but u have to take great risk of sideeffects cause its not clean enough.


For i m a shareholder in Clinuvel for many years i have still full confidence that we get
our full return,and our piece of this big cake.
I m sure shareprice will recover,only thing u need is patience,patience and patience ! smile.gif
  Forum: By Share Code


Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING